Boston Scientific Corporation BSX
Composite 57/100; the shares have moved about 41% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 19/100 — a strong mark against it.
Growth ranks 83/100 — a strong point in its favour. Quality ranks 65/100 — a moderate point in its favour. Balance-sheet strength ranks 63/100 — a moderate point in its favour.
Momentum ranks 19/100 — a strong mark against it.
What the company does Boston Scientific designs and markets medical devices across MedSurg and Cardiovascular segments, including stents, scopes, neuromodulation systems, and urological implants.
Key financials Revenue grew 19.9% with EPS up 55.8%. Margins: gross 69.2%, operating 22.9%, net 17.5%. ROE 15.3%, ROA 6.2%, ROCE 10.9%. Debt/Equity 0.50, net debt/EBITDA 2.12.
Stock health Momentum is weak: -4.54% (3m), -34.44% (6m), -54.17% (12m). Sideravia scores: Quality 64.5, Growth 82.5, Momentum 19.6. RSI(14) at 47.30.
Price vs fair value The stock trades at a discount of 30.10% versus the analyst mean target of 62.69. - Recent cyberattack caused global disruption to shipments (TechCrunch) - Product recall pressured shares by 5% (Motley Fool) - Sector-wide healthcare decline amplified losses (MT Newswires)
Looking forward Forward P/E 15.34 and PEG 0.46 suggest potential margin expansion. Valuation percentile 46.9/100 indicates fair value alignment.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.